http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2542667-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61019b9e8aa5f5158c56a22f22016444 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-099 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 |
| filingDate | 2008-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_161f6ae3dc23b08cf0fdbb55be9d0d49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_982635341292af1a798cb5efb1b41e8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83883cf0a387557442d128bdceea781d |
| publicationDate | 2015-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2542667-C2 |
| titleOfInvention | IMPROVED Bordetella pertussis VACCINES BASED ON MUTANT GLYCOSYLTRANSFERASES LPS |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to biotechnology and immunology. What is presented is a host cell of Bordetella pertussis, Bordetella bronchiseptica or Bordetella parapertussis, which is used as an adjuvant or for preventing or treating whooping cough, having the low activity of endogenous glycosyltransferase at least 98% identical to the amino acid sequence SEQ ID NO: 2 as compared to the activity of glycosyltransferase of a relative parent strain, wherein the low activity is ensured by using an inactivating vector, which causes the inactivation of expression of a sequence of endogenous nucleic acid coding glycosyltransferase, or reduces to a low level of expression of the sequence of endogenous nucleic acid coding glycosyltransferase by the fusion of nucleic acid coding glycosyltransferase with a low-level or inducible promotor. What is disclosed is a preparation consisting of LPS of the above host cell with an increased replacement of hexosamine 1' or 4' phosphate groups of LPS referred to a lipid A, as compared to a LPS preparation from the related parent strain; thereby LPS is characterised by producing at least 8 ions in the ESI-MS spectrum, wherein the preparation is used as an adjuvant or for preventing or treating whooping cough. What is presented is using the above host cells or the LPS preparation for producing the preparation for preventing and/or treating whooping cough, or producing the drug preparation for immunising a mammal, wherein the host cells or LPS is used as an adjuvant. What is described is a pharmaceutical composition used as the adjuvant or for preventing or treating Bordetella infection containing the above host cell or above LPS preparation in an effective amount and a pharmaceutically acceptable carrier. n EFFECT: invention enables producing the pharmaceutical preparation of Bordetella cells or LPS, possessing the high immunogenicity as compared to the preparation of the related parent strain Bordetella. n 12 cl, 7 dwg, 3 tbl, 1 ex |
| priorityDate | 2007-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 234.